CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
AstraZeneca
Acerta Pharma BV
Center for International Blood and Marrow Transplant Research
Mayo Clinic
Center for International Blood and Marrow Transplant Research
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
UNC Lineberger Comprehensive Cancer Center
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
UNC Lineberger Comprehensive Cancer Center
Novartis
Juno Therapeutics, a Subsidiary of Celgene
UNC Lineberger Comprehensive Cancer Center
The Lymphoma Academic Research Organisation
Cothera Bioscience, Inc
Zhejiang DTRM Biopharma
Oncternal Therapeutics, Inc
University Hospital Muenster
Celgene
AO GENERIUM
Odense University Hospital
Nordic Nanovector
Celgene
Sunnybrook Health Sciences Centre
Oncternal Therapeutics, Inc
University Hospital Olomouc
Takeda
miRagen Therapeutics, Inc.
AbbVie
University of California, San Francisco
Fondazione Italiana Linfomi - ETS
Takeda
miRagen Therapeutics, Inc.
Amgen Research (Munich) GmbH
LEO Pharma
Seagen Inc.
Seagen Inc.
Nordic Nanovector
Eisai Inc.
City of Hope Medical Center
Fudan University
University of North Carolina, Chapel Hill
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH
Novartis
Seagen Inc.